Deutsche Bank Questions Long-Term Efficacy Of Sarepta's Eteplirsen Following Trial News
July 10, 2014 at 15:24 PM EDT
Shares of Sarepta Therapeurics (NASDAQ: SRPT) plummeted 28.2 percent Thursday morning following the long-term outcomes from the Phase ...